Pharvaris N.V. (NASDAQ:PHVS) Given Average Rating of “Moderate Buy” by Analysts

Pharvaris N.V. (NASDAQ:PHVS) has been given an average rating of “Moderate Buy” by the thirteen analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $49.1818.

Several research analysts recently weighed in on PHVS shares. Royal Bank Of Canada decreased their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Wolfe Research started coverage on shares of Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Citizens Jmp reduced their price target on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 13th. Finally, Wedbush increased their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $32.80 on Friday. The company’s 50-day moving average price is $30.02 and its 200-day moving average price is $27.74. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -10.31 and a beta of -2.35. Pharvaris has a 12-month low of $16.72 and a 12-month high of $34.41.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.12. On average, sell-side analysts predict that Pharvaris will post -3.22 earnings per share for the current year.

Insider Transactions at Pharvaris

In related news, insider Peng Lu sold 15,000 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.24, for a total value of $453,600.00. Following the completion of the sale, the insider owned 66,083 shares of the company’s stock, valued at $1,998,349.92. This trade represents a 18.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Berndt Modig sold 23,333 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $27.74, for a total value of $647,257.42. Following the completion of the sale, the chief executive officer directly owned 142,084 shares of the company’s stock, valued at $3,941,410.16. The trade was a 14.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 214,909 shares of company stock valued at $6,421,745. 11.84% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. General Atlantic L.P. increased its holdings in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC grew its stake in shares of Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after purchasing an additional 368,000 shares during the period. venBio Partners LLC grew its stake in shares of Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after purchasing an additional 350,000 shares during the period. Deerfield Management Company L.P. grew its stake in shares of Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after purchasing an additional 425,000 shares during the period. Finally, Commodore Capital LP grew its stake in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after purchasing an additional 507,043 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.